The UK Vaccine Taskforce: securing access to vaccines
Kate Bingham, Chair of the UK Vaccine Taskforce, discusses the three goals of the taskforce.
The UK Vaccine Taskforce has three key goals: to secure...
COVID-19 and mental health at work and school
The COVID-19 pandemic has created a growing mental health crisis.
Isolation, uncertainty, and fear have all been significant factors in worsening mental health during the...
Prion disease: potential treatment discovered by researchers
Researchers have discovered a possible effective treatment strategy for patients suffering from prion disease.
The study, published in Nucleic Acids Research by Oxford University Press,...
“The science should not get in the way”
With more than a quarter of the world’s confirmed cases of COVID-19, can the USA reopen?
More than 25% of all confirmed cases of COVID-19...
Rare diseases: innovation, collaboration, and genomics
Professor Hackett discusses public-private collaboration, secure data sharing, and the potential of genomic sequencing for the treatment of rare diseases.
Professor Joanne Hackett, General Partner,...
Promise of a new route of treatment for Huntington’s Disease
An enzyme has been identified that can pave the way for the development of a new route of treatment for Huntington's Disease.
Scientists at EPFL's...
“The case for action on obesity has never been stronger”
Public Health England has launched a campaign to address obesity, a key risk factor in COVID-19.
Following a growing body of evidence that being overweight...
Fighting for a life unlimited with the Cystic Fibrosis Trust
Dr Lucy Allen, Director of Research at the Cystic Fibrosis Trust, speaks with HEQ about cystic fibrosis research, treatment and innovation.
Founded in 1964, the...
Innovation, technology, and evidence-based treatment for spinal cord injury
HEQ explores innovation in the treatment of spinal cord injury.
Injuries to the spinal cord, whether they are caused by an acute trauma such as...
Farxiga meets endpoints in trial for the treatment of chronic kidney disease
Farxiga has been shown to significantly reduce the worsening of renal function or risk of death in patients with chronic kidney disease with and...
Molecular cause explains a genetic form of microcephaly
Scientists have helped to explain a genetic form of microcephaly by uncovering a molecular cause for the rare disease.
Microcephaly is a condition where babies'...
World Obesity Federation: obesity, wellbeing, and COVID-19
World Obesity Federation President Professor John Wilding explores the mental and physical issues surrounding obesity and weight management and the links to COVID-19.
Obesity is...
Three new diagnostic kits launched for COVID-19 and respiratory illnesses
Three new diagnostic kits have been launched to help with the diagnosis of COVID-19 and other respiratory illnesses.
BATM, a leading provider of real-time technologies...
The ABC-Cancer project: diagnosis and screening for colorectal cancer
Maastricht University Professor Frederik-Jan van Schooten and Assistant Professor Dr Agnieszka Smolinska tell HEQ about the need for non-invasive biomarker testing for colorectal cancer.
HEQ...
UK secures access to 90 million doses of potential COVID-19 vaccine
The UK Government has today announced it has secured early access to 90 million doses of a potential COVID-19 vaccine.
Announced by Business Secretary Alok...
Farxiga granted Fast Track Designation for heart failure treatment
The drug Farxiga has been granted Fast Track Designation in the US for evaluation in the treatment of heart failure.
AstraZeneca has been granted Fast...
Potential treatment for rare degenerative disease discovered
Researchers have discovered a potential treatment for the rare Wolfram Syndrome – a degenerative disease.
Researchers from Yale have uncovered the mechanism behind a rare...
Bridging the gap in heart failure awareness
While heart failure affects 64 million people worldwide, a new Global survey shows that heart failure is a ‘blind spot’ for the public and...
MicroRNA antiviral rescue treatment for COVID-19
OmniSpirant Ltd is developing an extracellular vesicle microRNA antiviral rescue treatment for COVID-19 to dampen exaggerated immune responses and combat inflammation.
OmniSpirant is an Irish...
Gut health: “You need to introduce a systemic change”
Ali Kazemi, founder of nature-derived healthcare solution provider Metaceutic, tells HEQ about the holistic importance of gut health.
CEO Ali Kazemi, PhD, founded Copenhagen-based Metaceutic...
